CRMD Stock Analysis: Buy, Sell, or Hold?
CRMD - CorMedix Inc.
$7.68
-0.25 (-3.22%)
▼
5d:
-3.09%
30d:
+7.64%
90d:
+4.56%
BUY
MODERATE Confidence
Analysis Updated: May 15, 2026 12:00 AM ET
Earnings: May 14, 2026
0d
Smart Money Accumulation
CRMD is down 6.8% this week, but smart money is accumulating calls. Top strike: $9 2026-06-18 with 4,722 OI. Call ratio: 62% View Scanner →
Strength: 4.6/10
Get Alerted When CRMD Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
15 traders called CRMD this week
83% bullish • 4 bearish
83% bullish • 4 bearish
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: CRMD shows positive signals but monitor for confirmation. Market pricing in 15.0% growth. Moderate conviction.
💡 BUY OPPORTUNITY: CRMD shows positive signals but monitor for confirmation. Market pricing in 15.0% growth. Moderate conviction.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$4.55
Based on -2.5% avg growth
INTRINSIC VALUE TODAY
$2.83
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 7.2x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: CRMD is currently trading at $7.67, which is considered slightly high relative to its 30-day fair value range of $7.26 to $7.79. From a valuation perspective, the stock is trading at a premium (Forward PE: 11.0) compared to its historical average (7.2). At these levels, the market is pricing in 15.0% annual earnings growth.
Technical Outlook: Technically, CRMD is in a downtrend. Immediate support is located at $7.43, while resistance sits at $8.94. Short-term momentum is weak, with the stock down 3.2% recently.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $15.00 (+89.2%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, CRMD is in a downtrend. Immediate support is located at $7.43, while resistance sits at $8.94. Short-term momentum is weak, with the stock down 3.2% recently.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $15.00 (+89.2%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
SLIGHTLY HIGH
Historical Trading Range
$7.26 -
$7.79
Company Quality Score
56/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
63.8%
All Signals
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-3.2%)
- BULLISH: Trading 89.2% below Wall St target ($15.00)
- BULLISH: Expecting earnings turnaround to 15.0% growth with 312.1% revenue growth
Trading Range Analysis
30-Day Trading Range
$7.26 -
$7.79
Current vs Trading Range
SLIGHTLY HIGH
Support & Resistance Levels
Support Level
$7.43
Resistance Level
$8.94
Current Trend
Downtrend
Technical data as of
May 15, 2026
Fundamental Context
Forward P/E (Next Year Est.)
11.01
Wall Street Target
$15.00
(+89.2%)
Revenue Growth (YoY)
312.1%
Earnings Growth (YoY)
-28.3%
Profit Margin
52.3%
Valuation Premium vs History
+15.0% premium
PE vs Historical
11.0 vs 7.2
STRETCHED
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+15.0%
(market-implied from PE analysis)
1-Year Target
$9.12
(+15%)
2-Year Target
$10.49
(+32%)
3-Year Target
$12.06
(+52%)
3-Yr Target (if PE normalizes)
(PE: 11→7)
PE COMPRESSION
$7.88
(-1%)
Earnings growth offset by PE compression
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 22.0, Growth: -8.9%)
$12.01
(+52%)
Base:
(SPY PE: 11.0, Growth: -8.9%)
$6.00
(-24%)
Bear:
(PE: 7.2, Growth: -8.9%)
$3.92
(-51%)
📈
Valuation based on Current Earnings
Trailing PE: 3.68 | Current EPS (TTM): $2.04
Bull Case
$4.13
(-48%)
Analyst growth -50.0%, PE expands to 4.0
Base Case
$3.75
(-53%)
Market implied -50.0%, PE stable at 3.7
Bear Case
$5.10
(-36%)
Severe decline -20.0%, PE contracts to 3.1
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
Share & Embed Analysis
Last updated: May 15, 2026 2:40 PM ET
Data refreshes hourly during market hours. Next update: 3:40 PM
Data refreshes hourly during market hours. Next update: 3:40 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is CRMD showing a specific setup today?
Insider Activity (6 Months)
0
Buys
3
Sells
Net
INSIDERS SELLING
Recent Transactions
Alan W Dunton
SELL
20000 shares
2025-12-30
Joseph Todisco
SELL
30000 shares
2025-12-18
Steven W Lefkowitz
SELL
40000 shares
2025-12-09
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
VRTX
Vertex Pharmaceuticals I… |
BUY
34 analysts |
$550 | 65 BUY |
|
LEGN
Legend Biotech Corp |
STRONG BUY
22 analysts |
$57 | 57 HOLD |
|
REGN
Regeneron Pharmaceutical… |
STRONG BUY
25 analysts |
$875 | 53 HOLD |
|
XENE
Xenon Pharmaceuticals Inc |
STRONG BUY
19 analysts |
$79 | 56 HOLD |
|
RARE
Ultragenyx |
STRONG BUY
20 analysts |
$53 | 55 HOLD |
Advanced CRMD Option Strategies
Professional options setups generated by AI based on today's CRMD price and gamma walls.
